Your browser doesn't support javascript.
loading
Safety and Efficacy of Add on Modafinil to Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Article Dans Anglais | IMSEAR | ID: sea-159218
ABSTRACT

Aim:

Despite the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of major depression, a significant number of patients show partial or no remission of symptoms. Although antidepressant medications are effective, they have a delayed onset of therapeutic effect. Modafinil is a novel psychostimulant that may be helpful in treating patients with residual symptoms of depression. The efficacy of modafinil as add-on therapy to SSRIs in depressed patients in Indian population is lacking; hence this study was designed to study the efficacy and safety of Modafinil as add-on therapy to SSRI in depressed patient in Indian Population.

Methods:

In an open, randomized study, 50 patients diagnosed with major depressive disorder (MDD) were divided into two groups. In Group A (n = 25) patients received conventional SSRIs with low dose Modafinil for 8 weeks. In Group B (n = 25) patients received conventional SSRIs for 8 weeks. Patients were evaluated at baseline and then at the end of 2, 4, 6, and 8 weeks.

Results:

There was significant improvement in Hamilton depression rating scale (HDRS), Epworth Sleepiness Scale (ESS), Fatigue severity Scale (FSS) and Clinical Global Improvement – severity (CGI-S) Scale (p < 0.05) in both groups. Modafinil in low dose as add on therapy showed more decrease in scores, had earlier onset of action, as compared to conventional treatment (p < 0.05). No serious adverse event was reported in either of the groups.

Conclusion:

Low dose Modafinil as add-on therapy had shown better efficacy, earlier onset of action as compared to conventional treatment in MDD in Indian patients.
Sujets)

Texte intégral: Disponible Indice: IMSEAR (Asie du Sud-Est) Sujet Principal: Composés benzhydryliques / Humains / Inbiteurs sélectifs de la recapture de la sérotonine / Trouble dépressif majeur / Association de médicaments / Inde Type d'étude: Essai clinique contrôlé Pays comme sujet: Asie langue: Anglais Année: 2010 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: IMSEAR (Asie du Sud-Est) Sujet Principal: Composés benzhydryliques / Humains / Inbiteurs sélectifs de la recapture de la sérotonine / Trouble dépressif majeur / Association de médicaments / Inde Type d'étude: Essai clinique contrôlé Pays comme sujet: Asie langue: Anglais Année: 2010 Type: Article